Project Details
Projekt Print View

Inhibition of TMEM16 proteins to attenuate mucus secretion and to improve airway clearance

Subject Area Anatomy and Physiology
Pneumology, Thoracic Surgery
Cell Biology
Term from 2018 to 2023
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 407638684
 
Final Report Year 2024

Final Report Abstract

The main conclusions from the present comprehensive study are: 1) TMEM16 proteins (anoctamins) are proinflammatory, prosecretory and proproliferative in airways, intestine, and other tissues. 2) Inhibitors of TMEM16 reduce inflammation, bronchoconstriction, and mucus secretion in airways and intestine while activators of TMEM16 show opposite effects. 3) Inhibitors of TMEM16A are beneficial in the treatment of inflammatory airway diseases such as asthma, COPD, CF, and COVID-19 in mouse and human. 4) We propose low dose systemic application of niclosamide or benzbromarone, or high topical aerosol application of either compound to reduce inflammation along with mucus hypersecretion, bronchospasm, and pulmonary arterial hypertension in asthma, COPD and CF. Niclosamide is proposed as a treatment in severe COVID-19 and other highly inflammatory airway diseases.

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung